Genesee Capital Advisors’s Eli Lilly LLY Stock Holding History

Genesee Capital Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$292K	Sell	244 -12	-5%	-$12.3K	0.09%	133
2026 Q1	$235K	Sell	256 -1	-0.4%	-$1.01K	0.1%	120
2025 Q4	$277K	Sell	257 -148	-37%	-$142K	0.11%	106
2025 Q3	$309K	Buy	405 +1	+0.2%	+$744	0.13%	94
2025 Q2	$315K	Hold	404	–	–	0.14%	97
2025 Q1	$334K	Buy	404 +1	+0.2%	+$832	0.17%	97
2024 Q4	$311K	Hold	403	–	–	0.14%	101
2024 Q3	$357K	Sell	403 -26	-6%	-$23.4K	0.17%	89
2024 Q2	$389K	Hold	429	–	–	0.19%	82
2024 Q1	$334K	Buy	429 +1	+0.2%	+$712	0.18%	82
2023 Q4	$250K	Buy	+428	New	+$250K	0.15%	89

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Genesee Capital Advisors's LLY Position: Q2 2026 in Review

Genesee Capital Advisors reduced its Eli Lilly (LLY) stake by 4.7% in Q2 2026, selling an estimated $12.3K and leaving 244 shares worth $292K. The position accounts for 0.09% of the portfolio, ranked #133.

Genesee Capital Advisors first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. The position peaked at $389K in Q2 2024. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Genesee Capital Advisors held 244 shares of Eli Lilly worth $292K as of Q2 2026.
Genesee Capital Advisors sold 12 Eli Lilly shares in Q2 2026, an estimated $12.3K.
Eli Lilly made up 0.09% of Genesee Capital Advisors's portfolio in Q2 2026, its #133 holding.
Genesee Capital Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
Genesee Capital Advisors's Eli Lilly position peaked at $389K in Q2 2024.
4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Genesee Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.